L
Lewis J. Rubin
Researcher at University of California, San Diego
Publications - 373
Citations - 60316
Lewis J. Rubin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Bosentan. The author has an hindex of 101, co-authored 370 publications receiving 57044 citations. Previous affiliations of Lewis J. Rubin include University of Texas Health Science Center at San Antonio & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Melody-1: a pilot study of macitentan in pulmonary hypertension due to left ventricular dysfunction
Jean-Luc Vachiery,Marion Delcroix,Hikmet Al-Hiti,Michela Efficace,Martin Hutyra,Gabriela Lack,Kelly Papadakis,Lewis J. Rubin +7 more
TL;DR: A randomized, double blind, phase 2 MELODY-1 study evaluated macitentan for pulmonary hypertension (PH) due to left heart disease in patients with combined post- and pre-capillary PH.
Journal ArticleDOI
Pulmonary Hypertension Overlap Syndromes: A Real Entity?
Ori Ben-Yehuda,Lewis J. Rubin +1 more
TL;DR: The most widely accepted classification of pulmonary hypertension (PH) has relied on a series of conferences termed the World Symposia on Pulmonary Hypertension.
Journal Article
Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study
Nazzareno Galiè,Friedrich Grimminger,Ekkehard Grünig,Marc Humbert,Zhi-Cheng Jing,Anne Keogh,David Langleben,Lewis J. Rubin,Michael Ochan Kilama,Arno Fritsch,Neil Davie,Hossein Ardeschir Ghofrani +11 more
TL;DR: Improvements in exercise capacity and hemodynamics underline the efficacy of riociguat in the investigated PAH cohort.
Journal ArticleDOI
P66: Nebulized inhaled nitrite (AIR001) for pulmonary arterial hypertension: Studies to determine safety, pharmacokinetics, and maximum tolerated dose, lack of pharmacodynamic interaction with sildenafil and optimal nebulizer device
TL;DR: Inhaled AIR001 is well tolerated up to doses of 90 mg (loaded dose), and early dose effects are ameliorated upon repeat dosing, both in the absence and presence of sildenafil.
Journal ArticleDOI
Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
Otylia Kowal-Bielecka,Jérôme Avouac,David Pittrow,Doerte Huscher,Frank Behrens,Christopher P. Denton,Ivan Foeldvari,Marc Humbert,Marco Matucci-Cerinic,Peter Nash,Christian Opitz,Lewis J. Rubin,James R. Seibold,Vibeke Strand,Daniel E. Furst,Oliver Distler +15 more
TL;DR: In this article, the validity status of the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the 36-item Medical Outcomes Study Short Form Health Survey (SF-36) was assessed in patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc).